Selcodebart

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** A humanized monoclonal antibody directed against the bone morphogenetic proteins (BMPs) co-receptor hemojuvelin (HJV), with potential to treat anemia of inflammation and other forms of anemia. Upon subcutaneous administration, selcodebart targets and binds to HJV, preventing it from binding to the hepcidin regulatory ligands BMPs and inhibiting the HJV-mediated signaling pathway. This suppresses hepcidin synthesis and increases iron availability, which may normalize plasma iron levels and increase erythropoiesis. HJV is required for hepcidin production. Hepcidin plays a key role in the homeostasis of systemic iron by restricting iron absorption and inhibiting ferroportin-mediated iron export; it is upregulated during acute and chronic inflammation in response to cytokines and, in certain cancers, may contribute to cancer-associated anemia.

**Synonyms:** - Anti-HJV Monoclonal Antibody DISC-0974 - Anti-Hemojuvelin Monoclonal Antibody DISC-0974 - DISC 0974 - DISC-0974 - DISC0974 - SELCODEBART